Diseases /

Acute Myeloid Leukemia Not Otherwise Specified

Back to Diseases List
Associated Genetic Biomarkers

Overview

NCI Definition: Acute myeloid leukemias that do not fulfill the criteria for inclusion in the group of acute myeloid leukemias which have recurrent genetic abnormalities or myelodysplastic changes, or are therapy-related. This category includes entities classified according to the French-American-British classification scheme. [1]

Acute myeloid leukemia not otherwise specifieds most frequently harbor alterations in DNMT3A, RUNX1, TET2, ASXL1, and SRSF2 [2].

Most Commonly Altered Genes in Acute Myeloid Leukemia Not Otherwise Specified

DNMT3A Mutation, SRSF2 Mutation, SRSF2 Exon 1 Mutation, RUNX1 Mutation, and IDH2 Mutation are the most common alterations in acute myeloid leukemia not otherwise specified [2].

Top Alterations in Acute Myeloid Leukemia Not Otherwise Specified

Clinical Trials

View Clinical Trials for Acute Myeloid Leukemia Not Otherwise Specified

Disease Details

Synonyms
Acute myeloid leukemia (AML) (NOS), Acute Myeloid Leukemia Not Otherwise Categorized, Acute Myeloid Leukemia NOS, PEDIATRIC Acute myeloid leukemia (AML) (NOS), AML, NOS, Acute myeloid leukemia, Acute Myeloid Leukemia, NOS
Parent(s)
Acute Myeloid Leukemia
Children
Acute Myeloid Leukemia without Maturation, Acute Megakaryoblastic Leukemia, Acute Myeloid Leukemia with Maturation, Acute Erythroid Leukemia, Acute Basophilic Leukemia, Acute Monoblastic and Monocytic Leukemia, Acute Myelomonocytic Leukemia, Acute Myeloid Leukemia with Minimal Differentiation, and Acute Panmyelosis with Myelofibrosis
OncoTree Name
AML, NOS
OncoTree Code
AMLNOS

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.